A Phase II Trial of Perioperative Camrelizumab Plus Neoadjuvant Chemotherapy in Resectable Stage IIB–IIIB Lung Squamous Cell Carcinoma
MedComm · 2026-07 · 7 (7)
DOI: 10.1002/mco2.70793 ↗Kurz gefasst
Fachartikel in der Zeitschrift MedComm, online erschienen am 15.06.2026. Verfasst von Mingming Hu und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology Beijing Chest Hospital, Capital Medical University Beijing China. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
This phase II trial investigated perioperative camrelizumab plus neoadjuvant chemotherapy for patients with stage IIB–IIIB lung squamous cell carcinoma (LUSC) and explored predictive biomarkers of treatment response. Patients received neoadjuvant camrelizumab (200 mg, Day 1) in combination with nab‐paclitaxel (130 mg/m 2 , Days 1 and 8) and carboplatin (area under the curve = 5, Day 1) every 3 weeks for two cycles, followed by surgery and adjuvant camrelizumab for 1 year. The primary endpoint was major pathological response (MPR) rate. Forty‐five patients were treated, of whom 41 underwent surgery. Twenty‐seven of 45 patients (60.0%) achieved MPR and 20 (44.4%) achieved pathological complete response (pCR). With a median follow‐up of 37.5 months, the 3‐year disease‐free survival and overall survival rates were 65.9% and 68.7%, respectively. Among eight patients with stage IIIB disease, three (37.5%) achieved pCR. Baseline neutrophil percentage and smoking history were associated with MPR. T‐cell receptor (TCR) sequencing revealed that three V‐J gene pairs in TCR beta clones differed between the pCR and non‐pCR groups. This study supports the application of perioperative immunotherapy combined with neoadjuvant chemotherapy in patients with resectable locally advanced LUSC. The identification of blood biomarkers for precise patient selection warrants further in‐depth investigation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology Beijing Chest Hospital, Capital Medical University Beijing China.
- Laboratory For Clinical Medicine Capital Medical University Beijing China.
- Department of Thoracic Surgery Beijing Chest Hospital, Capital Medical University Beijing China.
- Department of Pathology Beijing Chest Hospital, Capital Medical University Beijing China.
ORCID-Profile: Tongmei Zhang
Zitieren
APA
Hu, M., Liu, S., Han, Y., Wang, F., Liu, Y., Lu, B., Li, H., Gao, Y., Wang, Y., Yang, W., Shi, K., Xiao, B., Wang, Q., Du, J., Lin, H., Li, X., Wang, C., & Zhang, T. (2026). A Phase II Trial of Perioperative Camrelizumab Plus Neoadjuvant Chemotherapy in Resectable Stage IIB–IIIB Lung Squamous Cell Carcinoma. MedComm, 7(7). https://doi.org/10.1002/mco2.70793
Vancouver
Hu M, Liu S, Han Y, Wang F, Liu Y, Lu B, et al. A Phase II Trial of Perioperative Camrelizumab Plus Neoadjuvant Chemotherapy in Resectable Stage IIB–IIIB Lung Squamous Cell Carcinoma. MedComm. 2026;7(7). doi:10.1002/mco2.70793
BibTeX
@article{Hu2026,
author = {Hu, Mingming and Liu, Shuku and Han, Yi and Wang, Feng and Liu, Yang and Lu, Baohua and Li, Hongxia and Gao, Yuan and Wang, Ying and Yang, Wei and Shi, Kang and Xiao, Bo and Wang, Qunhui and Du, Juan and Lin, Haifeng and Li, Xiaomi and Wang, Chong and Zhang, Tongmei},
title = {A Phase II Trial of Perioperative Camrelizumab Plus Neoadjuvant Chemotherapy in Resectable Stage IIB–IIIB Lung Squamous Cell Carcinoma},
journal = {MedComm},
year = {2026},
volume = {7},
number = {7},
doi = {10.1002/mco2.70793}
}
EUVIMED